Eagle Pharmaceuticals (EGRX +2.5%) has settled all patent issues with Eli Lilly (LLY -0.3%) related to the latter’s chemo drug Alimta (pemetrexed for injection).
Under the terms of the settlement agreement, Eagle will be allowed to initially enter the U.S. market with its alternative offering, Pemfexy, on February 1, 2022 followed by full commercial launch on April 1, 2022.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.